CONTINUE TRUSTING 1L ALECENSA
FOR PATIENTS WITH ALK+ ADVANCED NSCLC

Not a real patient.

PROVEN
PROTECTION

Sustained clinically meaningful PFS¹

mPFS: 34.8 months with ALECENSA vs 10.9 months with crizotinib

Learn more

SUPERIOR
SURVIVAL

6 out of 10 patients are alive at
5 years¹

OS rate: 62.5% with ALECENSA vs 45.5% with crizotinib; ALECENSA mOS yet to be reached

Learn more

REASSURING
EXPERIENCE

Sustained clinically meaningful improvement in quality of life²

5 month extension in HRQoL improvement vs crizotinib

Learn more

FAST FACTS

~70^%

of patients with ALK+ NSCLC have never smoked^3–6

FAST FACTS

>50^%

of patients with ALK+ NSCLC are younger than 60 years⁷

FAST FACTS

~30^%

of patients with ALK+ NSCLC have baseline CNS METASTASES at diagnosis^3,5,7

FAST FACTS

>50^%

of patients with ALK+ ADVANCED NSCLC receiving crizotinib progress within 1 year¹

FAST FACTS

>50^%

of patients with ALK+ ADVANCED NSCLC receiving crizotinib will not live past 5 years¹

1L: first line; ALK: anaplastic lymphoma kinase; HRQoL: health-related quality of life; mPFS: median progression-free survival; mOS: median overall survival; NSCLC: non small-cell lung cancer; OS: overall survival; PFS: progression-free survival; SmPC: Summary of Product Characteristics.

1. Mok T, et al. Ann Oncol 2020;31(8):1056–1064; 2. Pérol M, et al. Lung Cancer 2019;138:79–87; 3. Pacheco JM, et al. J Thorac Oncol 2019;14(4):691–700; 4. Du X, et al. Thorac Cancer 2018;9(4):423–430; 5. Patil T, et al. J Thorac Oncol 2018;13(11):1717–1726; 6. Gainor JF, et al. JCO Precis Oncol 2017;2017:PO.17.00063; 7. Johung KL, et al. J Clin Oncol 2016;34(2):123–129.

M-XX-00017121; Date of preparation: June 2024
Legal Statement
Privacy Policy
Cookie Preferences

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration, or usage in the country of your origin.

FOR HEALTHCARE PROFESSIONALS

Leaving website

CONTINUE TRUSTING 1L ALECENSA
FOR PATIENTS WITH ALK+ ADVANCED NSCLC

PROVEN
PROTECTION

SUPERIOR
SURVIVAL

REASSURING
EXPERIENCE

FOR HEALTHCARE PROFESSIONALS

Leaving website

CONTINUE TRUSTING 1L ALECENSA FOR PATIENTS WITH ALK+ ADVANCED NSCLC

PROVEN PROTECTION

SUPERIOR SURVIVAL

REASSURING EXPERIENCE

CONTINUE TRUSTING 1L ALECENSA
FOR PATIENTS WITH ALK+ ADVANCED NSCLC

PROVEN
PROTECTION

SUPERIOR
SURVIVAL

REASSURING
EXPERIENCE